BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
- Status
- RECRUITING
- Phase
- PHASE2
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
- Status
- RECRUITING
- Phase
- PHASE1
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Single cEll pRofiling PErsistaNce To ImmuNothErapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE2
NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
- Status
- RECRUITING
- Phase
- N/A
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
- Status
- RECRUITING
- Phase
- NA
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
- Status
- RECRUITING
- Phase
- PHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
- Status
- RECRUITING
- Phase
- PHASE1
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2